282 related articles for article (PubMed ID: 23068307)
1. Advances in stem cell mobilization.
Motabi IH; DiPersio JF
Blood Rev; 2012 Nov; 26(6):267-78. PubMed ID: 23068307
[TBL] [Abstract][Full Text] [Related]
2. Can every patient be mobilized?
DiPersio JF
Best Pract Res Clin Haematol; 2010 Dec; 23(4):519-23. PubMed ID: 21130416
[TBL] [Abstract][Full Text] [Related]
3. Advances in mobilization for the optimization of autologous stem cell transplantation.
Vose JM; Ho AD; Coiffier B; Corradini P; Khouri I; Sureda A; Van Besien K; Dipersio J
Leuk Lymphoma; 2009 Sep; 50(9):1412-21. PubMed ID: 19603345
[TBL] [Abstract][Full Text] [Related]
4. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?
Cashen AF; Lazarus HM; Devine SM
Bone Marrow Transplant; 2007 May; 39(10):577-88. PubMed ID: 17369869
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
6. New agents in HSC mobilization.
Domingues MJ; Nilsson SK; Cao B
Int J Hematol; 2017 Feb; 105(2):141-152. PubMed ID: 27905003
[TBL] [Abstract][Full Text] [Related]
7. New agents for mobilizing peripheral blood stem cells.
Greinix HT; Worel N
Transfus Apher Sci; 2009 Aug; 41(1):67-71. PubMed ID: 19615944
[TBL] [Abstract][Full Text] [Related]
8. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.
Veeraputhiran M; Jain T; Cronin S; Al-Kadhimi Z; Abidi MH; Ayash L; Mellert K; Lum LG; Ratanatharathorn V; Uberti JP; Deol A
J Clin Apher; 2014 Dec; 29(6):293-8. PubMed ID: 24700728
[TBL] [Abstract][Full Text] [Related]
9. Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells.
Gazitt Y
Curr Opin Hematol; 2002 May; 9(3):190-8. PubMed ID: 11953663
[TBL] [Abstract][Full Text] [Related]
10. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
Uy GL; Rettig MP; Cashen AF
Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
[TBL] [Abstract][Full Text] [Related]
11. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent.
Cashen AF; Nervi B; DiPersio J
Future Oncol; 2007 Feb; 3(1):19-27. PubMed ID: 17280498
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Flomenberg N; Comenzo RL; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
[TBL] [Abstract][Full Text] [Related]
13. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.
Pusic I; DiPersio JF
Curr Opin Hematol; 2010 Jul; 17(4):319-26. PubMed ID: 20473162
[TBL] [Abstract][Full Text] [Related]
14. In and out of the niche: perspectives in mobilization of hematopoietic stem cells.
Mohty M; Ho AD
Exp Hematol; 2011 Jul; 39(7):723-9. PubMed ID: 21624427
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
16. G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent.
Bendall LJ; Bradstock KF
Cytokine Growth Factor Rev; 2014 Aug; 25(4):355-67. PubMed ID: 25131807
[TBL] [Abstract][Full Text] [Related]
17. Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
Yoshifuji K; Toya T; Adachi H; Fujita M; Wada A; Konuma R; Kishida Y; Konishi T; Nagata A; Yamada Y; Kaito S; Kumagai T; Inamoto K; Akiyama M; Igarashi A; Najima Y; Doki N; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Int J Hematol; 2019 Jul; 110(1):115-118. PubMed ID: 30989487
[TBL] [Abstract][Full Text] [Related]
18. Mobilisation of haematopoietic stem cells in paediatric patients, prior to autologous transplantation following administration of plerixafor and G-CSF.
Patel B; Pearson H; Zacharoulis S
Pediatr Blood Cancer; 2015 Aug; 62(8):1477-80. PubMed ID: 25755177
[TBL] [Abstract][Full Text] [Related]
19. HIF-1α is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1α.
Forristal CE; Nowlan B; Jacobsen RN; Barbier V; Walkinshaw G; Walkley CR; Winkler IG; Levesque JP
Leukemia; 2015 Jun; 29(6):1366-78. PubMed ID: 25578474
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
